Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | ABL2 | P42684 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.42 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9928291 | 0.91 | EGFR (0.53) | EGFRERBB2ABL1ABL2AURKA | |
| SCHEMBL9903974 | 0.90 | EGFR (0.64) | EGFRERBB2ABL1ABL2AURKA | |
| SCHEMBL9943135 | 0.89 | EGFR (0.51) | EGFRERBB2ABL1ABL2AURKA | |
| SCHEMBL9928295 | 0.85 | EGFR (0.52) | EGFRERBB2ABL1ABL2AURKA | |
| SCHEMBL9928317 | 0.84 | EGFR (0.51) | EGFRERBB2ABL1ABL2AURKA | |
| SCHEMBL9897404 | 0.83 | EGFR (0.51) | EGFRERBB2ABL1ABL2AURKA | |
| SCHEMBL9896683 | 0.83 | EGFR (0.46) | EGFRERBB2ABL1ABL2AURKB | |
| SCHEMBL9896703 | 0.83 | EGFR (0.51) | EGFRERBB2ABL1ABL2AURKA | |
| SCHEMBL9896700 | 0.83 | EGFR (0.51) | EGFRERBB2ABL1ABL2AURKA | |
| SCHEMBL9896696 | 0.83 | EGFR (0.51) | EGFRERBB2ABL1ABL2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | ERBB2, EGFR, FGFR1 | EGFR 2/4885ERBB2 1/4885ABL1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.